Structural and analytical reference
Compare CJC-1295 and ipamorelin by structural class, sequence size and analytical identity, with a clear distinction between DAC and no-DAC terminology.
CJC-1295 belongs to the GHRH-analogue design family; ipamorelin is a distinct pentapeptide secretagogue. For CJC-1295, the presence or absence of the DAC modification must be resolved before comparing molecular records.
The comparison at a glance
| Attribute | CJC-1295 terminology | Ipamorelin |
|---|---|---|
| Structural class | GHRH/GRF-derived analogue | Synthetic pentapeptide secretagogue |
| Backbone context | Based on a modified GRF(1–29) design | Five-residue sequence |
| Defining identity issue | Albumin-reactive DAC modification versus a no-DAC declared structure | Nonstandard residues, D stereochemistry and C-terminal amide |
| Published ipamorelin sequence | Not applicable | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
The cited CJC-1295 discovery work concerns albumin-reactive bioconjugate chemistry. Catalog use of “CJC-1295 no DAC” commonly refers to modified GRF(1–29). The alias is not a substitute for a full sequence and modification declaration.
Separate backbone from conjugation
DAC identifies a chemical modification relevant to the CJC design, not a vial presentation or a purity category. Removing or changing a conjugating group changes the structure expected in an identity test. A molecular formula from a DAC reference should not be copied onto an unspecified no-DAC material.
Ipamorelin is not a shortened version of CJC-1295. Its sequence is a different design, including Aib and D-configured residues. NH2 at the end of the written sequence indicates a C-terminal amide; it is part of the molecular identity.
What to ask before reviewing a COA
- Which precise CJC structure is declared, including DAC status and terminal chemistry?
- Is the report for a single component or a blend?
- For a blend, what identity evidence is supplied for each named component?
- Are observed masses assigned to the correct structures and charge states?
An aggregate HPLC result does not establish the separate mass content of two components. Component identity, chromatographic behavior and quantitative composition are different questions. Keep them separate when reviewing a combined record.
Match the reference to the SRL material
SRL’s published CJC-1295 + Ipamorelin report is a blend record. It should be read as that tested sample, rather than as a certificate for an isolated peptide or every material using either name.
Use the DAC terminology guide when resolving the CJC designation. Keep the supplier’s declared structure, the report sample and the cited scientific material aligned before drawing an analytical comparison.
Frequently asked questions
Are CJC-1295 and ipamorelin the same kind of peptide?
They belong to different structural design classes and have different sequence architectures.
Can a DAC molecular profile be used for a no-DAC sample?
Only if the declared chemistry actually matches. The modification must be resolved first.
Does a blend report prove the ratio of its components?
Look for an explicit, suitable quantitative assay. A combined purity percentage alone does not establish a ratio.
Continue learning
Sources and scope
- Jetté et al. (2005), hGRF(1–29)-albumin bioconjugates and CJC-1295. Primary reference for the albumin-reactive CJC-1295 design.
- Raun et al. (1998), ipamorelin discovery. Primary sequence and receptor-class reference; no dosing guidance is reproduced here.
This original SRL reference uses the linked scientific and labeling records for molecular or analytical context. It does not reproduce an experimental protocol or certify a supplier batch. Prepared October 2, 2026.
